Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 6/20 | 0.42 |
| ▸ | SELP | P16109 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13077624 | 0.94 | SELE (0.45) | SELESELP | |
| SCHEMBL12240500 | 0.94 | SELE (0.48) | SELESELP | |
| SCHEMBL15434743 | 0.88 | SELE (0.40) | SELESELP | |
| SCHEMBL14823278 | 0.85 | SELE (0.53) | SELESELP | |
| SCHEMBL13570046 | 0.84 | SELE (0.33) | SELE | |
| SCHEMBL13657359 | 0.82 | SELE (0.43) | SELESELP | |
| SCHEMBL11982131 | 0.82 | SELE (0.45) | SELESELP | |
| SCHEMBL14823284 | 0.82 | SELE (0.45) | SELESELP | |
| SCHEMBL18938433 | 0.82 | SELE (0.47) | SELESELP | |
| SCHEMBL12246579 | 0.82 | SELE (0.49) | SELESELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023679-A1 | Compounds and methods for treatment of sickle cell disease or complications associated therewith | GLYCOMIMETICS, INC. (US) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023679-A1 | Compounds and methods for treatment of sickle cell disease or complications associated therewith | HBG1, HBG2, SORD | SELE 8/4885SELP 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.